BioVersys AG Launches IPO on SIX Swiss Exchange

BioVersys AG, a clinical stage biopharmaceutical company, has announced the launch of its Initial Public Offering (IPO) on the SIX Swiss Exchange. The IPO comprises up to 2,083,333 newly issued shares and an over-allotment option of up to 138,888 shares.

Each share is priced at CHF 36.00, targeting gross proceeds of approximately CHF 75 million, which could increase to CHF 80 million if the over-allotment option is fully exercised. BioVersys plans to use the majority of these funds for the development of its lead product, BV100. Remaining proceeds will support Alpibectir's advancement towards regulatory approval and the company's preclinical pipeline.

The offer period started on January 29 and runs until February 05, 2025, with trading expected to start on February 07. Key investors, including Glaxo Group Limited, have committed to significant financial contributions.